Picture [LSA] – The Business Web Portal 650x89px
Document › Details

Galapagos N.V.. (9/11/18). "Press Release: Gilead and Galapagos Announce Filgotinib Meets Primary and All Key Secondary Endpoints in First Phase 3 Study in Rheumatoid Arthritis". Foster City, CA & Mechelen.

Organisations Organisation Galapagos N.V. (Euronext + Nasdaq: GLPG)
  Group Galapagos (Group)
  Organisation 2 Gilead Sciences Inc. (Nasdaq: GILD)
  Group Gilead Sciences (Group)
Products Product filgotinib (GLPG0634)
  Product 2 clinical research
Index term Index term Gilead–Galapagos: filgotinib, 201512– license + collab developm ww partnership $300m upfront cash + $425m equity investment + milestones + royalties
Persons Person McHutchison, John (Gilead 201809 CSO)
  Person 2 Abi-Saab, Walid (Galapagos 201809 CMO)

Record changed: 2018-09-13


Picture [LSA] – The Business Web Portal 650x89px

More documents for Galapagos (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px

» top